CR20230382A - Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer - Google Patents
Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncerInfo
- Publication number
- CR20230382A CR20230382A CR20230382A CR20230382A CR20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- cancer
- treatment
- bicyclic
- tetrahydroazepine
- Prior art date
Links
- -1 Bicyclic tetrahydroazepine derivatives Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención proporciona nuevos derivados de tetrahidroazepina bicíclicos que tienen la Fórmula general (I) <img alt="" src="data:image/png;base64,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 (***)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21156877 | 2021-02-12 | ||
EP21186928 | 2021-07-21 | ||
PCT/EP2022/053257 WO2022171745A1 (en) | 2021-02-12 | 2022-02-10 | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230382A true CR20230382A (es) | 2023-09-06 |
Family
ID=80461879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230382A CR20230382A (es) | 2021-02-12 | 2022-02-10 | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4291558A1 (es) |
JP (1) | JP2024506339A (es) |
KR (1) | KR20230146052A (es) |
AU (1) | AU2022221124A1 (es) |
CA (1) | CA3210553A1 (es) |
CL (1) | CL2023002362A1 (es) |
CO (1) | CO2023010694A2 (es) |
CR (1) | CR20230382A (es) |
IL (1) | IL304595A (es) |
PE (1) | PE20231505A1 (es) |
TW (1) | TW202246257A (es) |
WO (1) | WO2022171745A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024033388A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533A (en) | 1837-12-26 | Truss for hermta | ||
US4943A (en) | 1847-01-26 | Harness-buckle | ||
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
DE69507956T2 (de) | 1994-07-21 | 1999-09-09 | Akzo Nobel Nv | Zyklische keton peroxyde zubereitungen |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
PT980244E (pt) | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
WO2003031376A1 (en) * | 2001-10-12 | 2003-04-17 | Aventis Pharmaceuticals Inc. | Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
EA026785B1 (ru) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Модуляторы индоламин 2,3-диоксигеназы и способы их применения |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2707308C (en) | 2007-11-30 | 2016-08-02 | Newlink Genetics Corporation | Ido inhibitors |
JP2011523616A (ja) | 2008-05-29 | 2011-08-18 | サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン | チタン酸アルミニウムを含有する多孔質構造体 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
RU2646139C1 (ru) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Анти-gitr-антитела |
ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
PL2542256T3 (pl) | 2010-03-04 | 2020-01-31 | Macrogenics, Inc. | Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
EP2882725A1 (en) * | 2012-08-09 | 2015-06-17 | F. Hoffmann-La Roche AG | Substituted hetero-azepinones |
HUE041851T2 (hu) * | 2015-03-02 | 2019-05-28 | Apeiron Biologics Ag | Neopláziás és/vagy fertõzõ betegségek kezelésére alkalmas biciklusos tetrahidrotiazepinszármazékok |
-
2022
- 2022-02-10 CR CR20230382A patent/CR20230382A/es unknown
- 2022-02-10 CA CA3210553A patent/CA3210553A1/en active Pending
- 2022-02-10 AU AU2022221124A patent/AU2022221124A1/en active Pending
- 2022-02-10 EP EP22706272.6A patent/EP4291558A1/en active Pending
- 2022-02-10 WO PCT/EP2022/053257 patent/WO2022171745A1/en active Application Filing
- 2022-02-10 KR KR1020237031032A patent/KR20230146052A/ko unknown
- 2022-02-10 PE PE2023002281A patent/PE20231505A1/es unknown
- 2022-02-10 JP JP2023548184A patent/JP2024506339A/ja active Pending
- 2022-02-11 TW TW111105035A patent/TW202246257A/zh unknown
-
2023
- 2023-07-19 IL IL304595A patent/IL304595A/en unknown
- 2023-08-10 CL CL2023002362A patent/CL2023002362A1/es unknown
- 2023-08-16 CO CONC2023/0010694A patent/CO2023010694A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2024506339A (ja) | 2024-02-13 |
PE20231505A1 (es) | 2023-09-26 |
KR20230146052A (ko) | 2023-10-18 |
IL304595A (en) | 2023-09-01 |
TW202246257A (zh) | 2022-12-01 |
EP4291558A1 (en) | 2023-12-20 |
CO2023010694A2 (es) | 2023-08-18 |
AU2022221124A1 (en) | 2023-08-03 |
CL2023002362A1 (es) | 2023-12-29 |
WO2022171745A1 (en) | 2022-08-18 |
CA3210553A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019231551A8 (en) | Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones | |
CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
CR20210247A (es) | Nuevos compuestos heterocíclicos | |
CR20230382A (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
TW200700422A (en) | Compounds for inhibiting ksp kinesin activity | |
DE602004021472D1 (en) | Pyrimiidinverbindungen | |
IN2014KN02886A (es) | ||
TW200700066A (en) | Compounds for inhibiting ksp kinesin activity | |
AU2003228770A8 (en) | Substituted pyrazolopyrimidines | |
DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
TW200510317A (en) | Caspase inhibitors and uses thereof | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MX2020010805A (es) | Inhibidores de bcl6. | |
MX2021012423A (es) | Métodos y composiciones para degradación de proteínas específicas. | |
MX2009006885A (es) | Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso. | |
MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
CR20230566A (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
CR20220116A (es) | Compuestos heterocíclicos | |
WO2018035346A8 (en) | KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER | |
CR20230496A (es) | Compuestos heterocíclicos | |
CR20220004A (es) | Nuevos compuestos heterocíclicos | |
MX2021002188A (es) | Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. | |
CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 |